Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.
Identifieur interne : 002309 ( PubMed/Curation ); précédent : 002308; suivant : 002310Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.
Auteurs : Pablo Martinez-Martin [Espagne] ; Eduardo Tolosa ; Basilio Hernandez ; Xavier BadiaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Anxiety, Cross-Sectional Studies, Educational Status, Female, Humans, Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Psychiatric Status Rating Scales, Psychometrics, Questionnaires, Reproducibility of Results, Sensitivity and Specificity, Severity of Illness Index, Speech Disorders (etiology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- etiology : Speech Disorders.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Anxiety, Cross-Sectional Studies, Educational Status, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Questionnaires, Reproducibility of Results, Sensitivity and Specificity, Severity of Illness Index.
Abstract
The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 +/- 1.8 in the group without WO, but 6.0 +/- 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.
DOI: 10.1002/mds.21944
PubMed: 18307246
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002309
Links to Exploration step
pubmed:18307246Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.</title><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="1"><nlm:affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health, Madrid, Spain. pmartinez@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author><author><name sortKey="Hernandez, Basilio" sort="Hernandez, Basilio" uniqKey="Hernandez B" first="Basilio" last="Hernandez">Basilio Hernandez</name></author><author><name sortKey="Badia, Xavier" sort="Badia, Xavier" uniqKey="Badia X" first="Xavier" last="Badia">Xavier Badia</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21944</idno><idno type="RBID">pubmed:18307246</idno><idno type="pmid">18307246</idno><idno type="wicri:Area/PubMed/Corpus">002309</idno><idno type="wicri:Area/PubMed/Curation">002309</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.</title><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="1"><nlm:affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health, Madrid, Spain. pmartinez@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author><author><name sortKey="Hernandez, Basilio" sort="Hernandez, Basilio" uniqKey="Hernandez B" first="Basilio" last="Hernandez">Basilio Hernandez</name></author><author><name sortKey="Badia, Xavier" sort="Badia, Xavier" uniqKey="Badia X" first="Xavier" last="Badia">Xavier Badia</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Anxiety</term><term>Cross-Sectional Studies</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Psychiatric Status Rating Scales</term><term>Psychometrics</term><term>Questionnaires</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Severity of Illness Index</term><term>Speech Disorders (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Speech Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anxiety</term><term>Cross-Sectional Studies</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term><term>Psychometrics</term><term>Questionnaires</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 +/- 1.8 in the group without WO, but 6.0 +/- 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18307246</PMID><DateCreated><Year>2008</Year><Month>05</Month><Day>01</Day></DateCreated><DateCompleted><Year>2008</Year><Month>08</Month><Day>06</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>830-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.21944</ELocationID><Abstract><AbstractText>The main objective of the present study was to test the validity of a 19-items instrument (QUICK Questionnaire, QQ) as a tool for screening of WO. Two hundred twenty-two patients (36.0% without WO; 64.0% with mild or moderate/severe WO) were included. Diagnosis of WO by the participant neurologist was considered the "gold standard." The complete Unified Parkinson's Disease Rating Scale battery, the Cumulative Illness Rating Scale-Geriatrics, and a form about WO presence and severity were completed by the neurologist. Patients independently completed the QQ just before the clinical assessment. As a whole, patients with WO were more disabled than patients without and patients with moderate/severe WO were in worse condition than patients with mild WO. The number of QQ symptoms declared to improve usually after the following dose of medication was 1.0 +/- 1.8 in the group without WO, but 6.0 +/- 3.8 in patients with WO (P < 0.001). A two QQ positive symptoms cut-off showed the following attributes: sensitivity, 88%; specificity, 80%; positive predictive value, 88.7%; negative predictive value, 79%; diagnostic accuracy, 85%; positive and negative likelihood ratios 4.4 and 0.15, respectively. The area under the ROC curve resulted 0.90 (CI95%: 0.86-0.94%). In summary, the QQ proved to be a valid screening tool to identify WO in PD patients. To our knowledge, the QQ is the only validated tool for diagnosis of WO.</AbstractText><CopyrightInformation>(c) 2008 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez-Martin</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroepidemiology Unit, National Centre for Epidemiology, Carlos III, Institute of Health, Madrid, Spain. pmartinez@isciii.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Basilio</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Badia</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><CollectiveName>ValidQUICK Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004522">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013064">Speech Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Arbelo</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arcaya</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayes</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campos</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catalán</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durán</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escamilla</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernández</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>García Ruiz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genís</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leiva</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lezcano</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martí</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martínez</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mínguez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morsi</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponce</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suárez</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viguera</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vivancos</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21944</ArticleId><ArticleId IdType="pubmed">18307246</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002309 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002309 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18307246
|texte= Validation of the "QUICK" questionnaire--a tool for diagnosis of "wearing-off" in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18307246" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |